Table 1 Patient inclusion characteristics and treatments taken over time by their SDAI group during the 10-year follow-up in the ESPOIR cohort
Patient characteristics | REM N = 48 | LDA N = 135 | MDA or HDA N = 69 | p-value |
|---|---|---|---|---|
Baseline characteristics | ||||
Age, years, mean (SD) | 45.0 (12.1) | 52.2 (10.9) | 49.7 (11.6) | < 0.01 |
Number of female subjects (%) | 38 (79) | 101 (75) | 57 (83) | NS |
Disease duration, months, mean (SD) | 7.8 (10.3) | 7.5 (9.2) | 8.5 (9.7) | NS |
RF, number (%) | 24 (50) | 58 (43) | 39 (57) | NS |
ACPA, number (%) | 19 (40) | 69 (51) | 26 (38) | NS |
Typical erosions, number of patients (%) | 20 (42) | 73 (54) | 40 (58) | NS |
ESR, mean (SD) | 30.2 (27.5) | 30.7 (25.8) | 32.1 (25.8) | NS |
CRP, mean (SD) | 23.8 (33.2) | 23.1 (32.3) | 29.0 (44.8) | NS |
mTSS, mean (SD) | 1.49 (1.95) | 3.38 (5.25) | 5.08 (8.03) | < 0.05 |
HAQ-DI, mean (SD) | 0.78 (0.59) | 0.94 (0.65) | 1.23 (0.68) | < 0.001 |
Smokers, number (%) | 29 (60) | 55 (40) | 34 (49) | NS |
Ten-year characteristics | ||||
Corticosteroids, number of patients (%) | 33 (69) | 112 (83) | 60 (87) | < 0.05 |
Corticosteroid cumulative dose, gr, mean (SD) | 1.3 (3.5) | 4.5 (6.9) | 7.4 (11.1) | < 0.001 |
DMARDs, number of patients (%) | 36 (75) | 120 (89) | 64 (95) | 0.01 |
DMARDs exposure duration, months, mean (SD) | 45.6 (115.4) | 89.6 (42.9) | 77.6 (43.2) | < 0.001 |
Methotrexate, number of patients (%) | 29 (60) | 111 (82) | 58 (84) | < 0.01 |
Methotrexate exposure duration, months, mean (SD) | 40 (46.5) | 75 (49.6) | 60.7 (48.7) | < 0.001 |
bDMARDs, number of patients (%) | 6 (13) | 32 (24) | 36 (92) | < 0.001 |
bDMARDs exposure duration, months, mean (SD) | 7.5 (24.3) | 13.4 (28.3) | 27.7 (35.9) | < 0.001 |
10-year mTSS, mean (SD) | 4.06 (4.75) | 14.59 (19.76) | 21.04 (24.08) | < 0.001 |
10-year HAQ, mean (SD) | 0.14 (0.33) | 0.53 (0.49) | 1.20 (0.62) | < 0.001 |